A phase II study of OSI-774 (NSC 718781) [erlotinib] in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2006 Results have been reported.
- 17 Sep 2005 New trial record.